1785
In the present study, arsenic trioxide was given intravenously for 42 days to a 56-year-old female patient suffering from chemotherapy/ATRA-resistant APL, with 43% APL blasts in the bone marrow and elevated D-dimers.
 56-year-old female patient: Subject; 56-year-old: Subject.Age; female: Subject.Gender; arsenic trioxide: Treatment; arsenic trioxide: Treatment.Drug; chemotherapy/ATRA-resistant APL: Treatment.Disorder; 42 days: Treatment.Duration
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 56-year-old female patient: Subject; 56-year-old: Subject.Age; female: Subject.Gender; arsenic trioxide: Treatment; arsenic trioxide: Treatment.Drug; chemotherapy/ATRA-resistant APL: Treatment.Disorder; 42 days: Treatment.Duration